Duke University School of Medicine
Durham, North Carolina, 27710, United States
NCT Number: NCT00229216
The purpose of this study is to confirm the safety and efficacy of oral tinidazole for the treatment of bacterial vaginosis.
Looking for future studies?
Notify Me18 year and older
Female
Interventional
Phase 3
Durham, North Carolina, 27710, United States
Tinidazole is a second-generation nitroimidazole i.e. an updated form of the standard drug used to treat bacterial vaginosis (metronidazole). Two dosing regimens are being compared to placebo to treat bacterial vaginosis, one of the most common vaginal infections.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Clinical and microbiological diagnosis of bacterial vaginosis -
Exclusion criteria
Other sexually transmitted disease
-
Mission Pharmacal
Industry
A Phase III Randomized, Multi-center, Double-blind, Double-dummy, Placebo-controlled Treatment Trial of Bacterial Vaginosis With Tinidazole Oral Tablets.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06438575
Bacterial Infections, Bacterial Infections and Mycoses
Pittsburgh, Pennsylvania, United States
View Trial DetailsNCT07418918
Bacterial Infections, Bacterial Infections and Mycoses
Chaozhou, Guangdong, China
View Trial DetailsNCT06985433
Bacterial Infections, Bacterial Infections and Mycoses
Odense C, Denmark
View Trial DetailsNCT07247851
Bacterial Infections, Bacterial Infections and Mycoses
Cairo, Abbasia, Egypt
View Trial Details